These data suggest that doxo-treated colon cancer cells exhibit dynamic changes in CD24, CD133 and CD44 antigen presentation, which may have the impact on e.g. the efficacy of CSC-targeted immunotherapy. Here, CD44 is linked to malignant colon neoplasm.